MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00417-026-07430-x

Медицинская библиотека · Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026

Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: a systematic review of diabetic retinopathy outcomes.

Francisco Catarina, Neves João Sérgio, Laiginhas Rita, Falcão Manuel

СтатьяОбзорПеревод пока не подготовлен

Аннотация

PURPOSE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of type 2 diabetes mellitus, offering glycemic, cardiovascular, and renal benefits; however, their impact on diabetic retinopathy (DR) remains uncertain.

METHODS

We conducted a PRISMA 2020-guided systematic review prospectively registered in PROSPERO (CRD420251237987). We searched bibliographic databases and ClinicalTrials.gov through 31 October 2025 for studies reporting DR outcomes in adults with type 2 diabetes treated with GLP-1 RAs.

RESULTS

Thirty-one studies were included: ten randomized evidence reports (five major randomized controlled trials (RCTs) and five RCT-derived secondary or post hoc analyses) and twenty-one observational/real-world studies. Heterogeneity in baseline DR status, outcome definitions, outcome ascertainment methods, and follow-up precluded quantitative pooling. Aside from SUSTAIN-6-where DR complications showed a signal consistent with early worsening in the setting of rapid HbA1c reduction-no randomized trial demonstrated increased DR progression. Major cardiovascular outcome trials (LEADER, REWIND, EXSCEL, HARMONY) reported neutral retinal outcomes but largely relied on adverse-event reporting rather than standardized ophthalmic grading. Real-world cohorts yielded heterogeneous estimates, and residual confounding cannot be excluded, particularly where baseline retinopathy severity was incompletely characterized.

CONCLUSION

Current evidence regarding the effects of GLP-1 RAs on DR outcomes remains inconsistent, with no convincing evidence supporting an intrinsic retinotoxic effect. These findings reinforce the importance of baseline ophthalmic assessment and closer monitoring when advanced pre-existing DR and rapid glycemic improvement is anticipated. Interpretation of the various studies remains limited by heterogeneity in methods, outcome definitions, follow-up duration, and the lack of standardized retinal assessment protocols, including best-corrected visual acuity, fundus photography and limited use of OCT to adequately evaluate both macular and peripheral retinal disease.

Для цитирования: Francisco Catarina, Neves João Sérgio, Laiginhas Rita, Falcão Manuel. Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: a systematic review of diabetic retinopathy outcomes.. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2026. DOI: 10.1007/s00417-026-07430-x.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.